Neurogranin as a Reliable Biomarker for Synaptic Dysfunction in Alzheimer’s Disease

Luisa Agnello 1, Bruna Lo Sasso 1,2, Matteo Vidal 3, Concetta Scazzone 1, Tommaso Piccoli 4, Caterina Maria Gambino 1, Giulia Bivona 1, Rosaria Vincenza Giglio 1, Anna Maria Ciaccio 5, Vincenzo La Bella 6 and Marcello Ciaccio 1,2,*

1 Department of Biomedicine, Neurosciences and Advanced Diagnostics, Institute of Clinical Biochemistry, Clinical Molecular Medicine and Clinical Laboratory Medicine, University of Palermo, 90127 Palermo, Italy; luisa.agnello@unipa.it (L.A.); bruna.lo.sasso@unipa.it (B.L.S.); concetta.scazzone@unipa.it (C.S.); cmgambino@libero.it (C.M.G.); giulia.bivona@unipa.it (G.B.); giglio.rosaria.vincenza@gmail.com (R.V.G.)
2 Department of Laboratory Medicine, Azienda Ospedaliera Universitaria Policlinico “P. Giaccone”, 90127 Palermo, Italy
3 Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy; matteo.vidali@gmail.com
4 Unit of Neurology, Department of Biomedicine, Neurosciences and Advanced Diagnostics, University of Palermo, 90127 Palermo, Italy; tommaso.piccoli@unipa.it
5 Unit of Clinical Biochemistry, University of Palermo, 90127 Palermo, Italy; annamaria.ciaccio@unipa.it
6 ALS Clinical Research Center, Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, 90129 Palermo, Italy; vincenzo.labella@unipa.it
* Correspondence: marcello.ciaccio@unipa.it; Tel.: +39-0916553296

Abstract: (1) Background: Neurogranin is a post-synaptic protein expressed in the neurons of the hippocampus and cerebral cortex. It has been recently proposed as a promising biomarker of synaptic dysfunction, especially in Alzheimer’s disease (AD). However, more efforts are needed before introducing it in clinical practice, including the definition of its reference interval (RI). The aim of the study was to establish the RI of cerebrospinal fluid (CSF) neurogranin levels in controls and individuals with non-neurodegenerative neurological diseases; (2) We included a total of 136 individuals that were sub-grouped as follows: AD patients (n = 33), patients with non-neurodegenerative neurological diseases (n = 70) and controls (33). We measured CSF neurogranin levels by a commercial ELISA kit. CSF RI of neurogranin was calculated by a robust method; (3) Results: AD patients showed increased levels of neurogranin. We also found that neurogranin was significantly correlated with T-tau, P-tau and mini mental state examination in AD patients. The lower and upper reference limits of the RI were 2.9 (90%CI 0.1–10.8) and 679 (90%CI 595–779), respectively; (4) Conclusion: This is the first study establishing the RI of CSF neurogranin.

Keywords: RC3; biomarkers; neurodegeneration; controls; diagnosis; prognosis; tau

1. Introduction

Neurogranin is a calmodulin-binding protein discovered in 1990, but only in recent years it gained attention as a potential biomarker of neurodegeneration [1]. The term “neurogranin” refers to its expression in granule-like structures within excitatory neurons of the hippocampus and cerebral cortex [2]. It is a post-synaptic protein with a pivotal role in regulating synaptic plasticity and function [3,4]. Neurogranin knockout mice display a decrease in long-term potentiation (LTP) induction and cognition, while upregulation promotes LTP and improves cognitive performance [5,6].

In the last few decades, research has focused on the possible role of neurogranin as a biomarker for synaptic dysfunction in neurodegenerative diseases, such as Alzheimer’s disease (AD) [7,8]. Synaptic dysfunction, indeed, represents an important phenomenon in AD pathophysiology, which occurs early in the disease course, and leads to reduced cognitive function [9]. Neurogranin levels have been found to be markedly reduced in...
the frontal cortex and hippocampus, whereas they are found to be increased in the CSF of AD patients, indicating loss of post-synaptic elements in the extracellular space [10–13]. Although some authors failed to find an association between neurogranin and AD, most of the studies showed that it is a reliable biomarker of synaptic dysfunction, especially in AD, as summarized in two recently published meta-analyses [14,15]. Additionally, a correlation between CSF neurogranin levels and brain atrophy, as well as amyloid load and cognitive decline, has also been reported [16]. Finally, increased CSF neurogranin levels have been proved to be predictive of progression to AD in patients with mild cognitive impairment (MCI) [17]. Taken together, evidence in the literature supports the role of neurogranin as a biomarker of synaptic dysfunction in patients with AD [18]. Accordingly, CSF neurogranin has been proposed to be integrated as a potential new biomarker of synaptic degeneration and loss in the (N) group of the novel criteria for the diagnosis of AD, which was published by the National Institute on Aging and Alzheimer’s Association’s (NIA-AA) research framework [19]. However, there are still some limitations in transferring neurogranin from bench to bedside, including the lack of a reference interval (RI) and decisional cut-off value. Indeed, establishing a RI and decisional cut off of neurogranin could help to appropriately evaluate the clinical usefulness of such biomarker in patients with neurodegenerative diseases and promote its introduction in clinical practice.

The aim of this study was to evaluate the role of neurogranin as a biomarker of synaptic dysfunction, especially in AD patients, for its potential diagnostic application.

2. Materials and Methods

2.1. Study Population

We performed a retrospective observational study at the Palermo University Hospital “P. Giaccone” on a population consisting of controls and patients with NNND, attending the ALS Clinical Research Center, Palermo, from 2000 to 2020, who underwent lumbar puncture for CSF analysis as part of their diagnostic evaluation. We also included AD patients enrolled at the Unit of Neurology, A.U.O.P “P. Giaccone”, Palermo, Italy. The diagnosis of AD and NNND was achieved by an expert neurologist based on medical history, clinical examination, neuropsychological testing, neuroimaging, fluorodeoxyglucose PET and CSF biomarker findings, according to the clinical diagnostic criteria of McKhann et al. and Albert et al. [20,21]. All the clinical and biological assessments were carried out in accordance with the Declaration of Helsinki and its amendments. The study protocol was approved by the Ethics Committee of the University Hospital of Palermo, and all participants gave written, informed consent that contained the following statement: “the biological material may also be used for research purposes”.

2.2. CSF Analysis

The CSF samples were collected between 8:00 a.m. and 10:00 a.m. from fasted patients, and were labeled to ensure anonymity. Specifically, the CSF was obtained by a lumbar puncture at the L3/4 or L4/5 interspace using a 21-gauge needle. It was collected in polypropylene tubes, centrifuged at 500 × g for 20 min, aliquoted in propylene tubes and stored at −80 °C until analysis, according to international consensus protocols [22].

CSF neurogranin levels were measured by a commercially available ELISA kit (Euroimmun, Lübeck, Germany), according to the manufacturer’s instructions.

The CSF β42, β40, P-tau and T-tau levels were measured by chemiluminescence enzyme immunoassay (CLEIA) (Lumipulse GpTau 181 and Lumipulse G Total Tau, Fujirebio Inc. Europe, Gent, Belgium) on a fully automated platform (Lumipulse G1200 analyzer, FujiRebio Inc. Europe, Gent, Belgium) according to the manufacturer’s instructions.

2.3. Statistical Analysis

Statistical analyses were performed by SPSS statistical software v.17.0 (SPSS Inc., Chicago, IL, USA), R Language v.4.0.3 (R Foundation for Statistical Computing, Vienna,
Austria) and MedCalc Statistical Software v. 20.011 (MedCalc Software Ltd., Ostend, Belgium). Normality distribution was assessed preliminarily by Q–Q plot and the Shapiro–Wilk test. Quantitative variables were expressed by the median and interquartile range (IQR), while qualitative variables were expressed as absolute and relative frequencies. Differences between the groups, for continuous variables, were estimated by the nonparametric Kruskal–Wallis test (if >2 groups) or Mann–Whitney U-test with Holm–Bonferroni’s method for multiple comparisons. With the Holm–Bonferroni method, a comparison was considered statistically significant if the p value was lower than 0.05/(N − r + 1), where N was the number of p values (in this study N = 15) and r was the rank of the sorted p values, ordered lowest to highest. The association between quantitative variables was evaluated by the nonparametric Spearman’s rank-order correlation. Diagnostic accuracy for the diagnosis of AD was evaluated by ROC curve analysis and reported as AUC with 95% confidence intervals calculated by the DeLong method. The best cut off was evaluated by the Youden index. The association between Alzheimer diagnosis and neurogranin levels was also evaluated by multivariate logistic regression.

RI was calculated by the robust method, an iterative process based on robust measures of location and spread, following the Box–Cox transformation (lambda = 0.461, shift = 0). The 90% CI of the reference interval was calculated by the bootstrap percentile method (10,000 bootstrap replicates). Outlier detection was performed on raw data using Hampel’s test for outliers.

3. Results

One hundred and thirty-six subjects were enrolled in this study. They were sub-grouped, according to previous clinical diagnosis, into AD (n = 33, 24.3%); patients with NNNDs, including patients with cerebrovascular diseases (n = 12, 8.8%), such as vascular encephalopathy and cerebral aneurysm, inflammatory CNS diseases (n = 10, 7.4%), such as myelitis and myeloradiculoneuritis, peripheral neuropathy (n = 41, 30.1%), such as muscular dystrophy and multifocal motor neuropathy, other neurological diseases (n = 7, 5.1%), such as epilepsy and brain cancer; and controls (n = 33, 24.3%). Demographic characteristics (sex and age) are shown in Table 1.

Table 1. Demographic characteristics and neurogranin levels.

| Group                               | Sex, M  | Age     | Neurogranin, pg/mL  |
|-------------------------------------|---------|---------|---------------------|
|                                     |         | (Median, IQR) | (Median, IQR)    |
| AD (n = 33)                         | 52%     | 71 (66–77)  | 401 (270–521)     |
| Cerebrovascular diseases (n = 12)   | 75%     | 60 (52–67)  | 114 (58–281)      |
| Inflammatory CNS diseases (n = 10)  | 30%     | 64 (58–76)  | 200 (76–303)      |
| Peripheral Neuropathy (n = 41)     | 61%     | 60 (48–71)  | 260 (89–352)      |
| Other neurological diseases (n = 7) | 43%     | 63 (48–72)  | 163 (38–338)      |
| Controls (n = 33)                   | 58%     | 52 (39–67)  | 109 (54–373)      |

| AD, Alzheimer’s disease; CNS, central nervous system; M, male sex; IQR, inter quartile range.

Neurogranin levels were significantly different among the groups (overall Kruskal–Wallis test p < 0.001) (Figure 1). In particular, taking into account Holm–Bonferroni’s method for multiple comparisons, AD patients displayed significantly higher median neurogranin levels than the controls (p < 0.001) and patients with cerebrovascular diseases (p < 0.001), inflammatory CNS diseases (p = 0.002) and peripheral neuropathy (p < 0.001). For the comparison of AD vs. other neurological diseases, the p value obtained (p = 0.015) was higher than the critical limit for significance calculated by the Holm–Bonferroni method (limit = 0.0045), which was then considered not significant. All other p values obtained were higher than 0.05 and ranged from 0.121 to 0.921. Neurogranin levels were also significantly higher in AD patients (n = 33) than patients of all NNNDs grouped together (n = 70) (median 401 vs. 212; p < 0.001). Moreover, a multivariate logistic regression using neurogranin, age and sex, confirmed that neurogranin was independently associated with
AD (OR 1.004, 95%CI 1.001–1.006). Similar results were obtained excluding controls from the multivariate model (OR 1.003, 95%CI 1.001–1.006).

Figure 1. Boxplots of neurogranin levels in the groups investigated. A (controls), B (Alzheimer), C (cerebrovascular disease), D (inflammatory CNS disease), E (peripheral neuropathy) and F (other neurological diseases).

The RI of neurogranin was calculated in the population, including both controls and patients with NNNDs (n = 103). Three outliers were identified and eliminated (respectively, 807, 819 and 924). Using the remaining data (n = 100), the lower and upper reference limits of the RI were 2.9 (90%CI 0.1–10.8) and 679 (90%CI 595–779), respectively.

The diagnostic performances of neurogranin for AD were evaluated by receiver operating characteristic (ROC) curve analysis (Figure 2). The area under the curve (AUC) was 0.78 (95%CI 0.69–0.87). According to Youden’s index, the best-calculated cut off was 319 pg/mL. At this cut off, sensitivity, specificity, positive predictive value and negative predictive values were 0.73, 0.73, 0.46 and 0.89, respectively.

Levels of CSF core biomarkers, namely amyloid β1-42 (β42), β1-40 (β40), total tau (T-tau), phosphorylated tau at threonine 181 (P-tau) and amyloid β1-42/β1-40 ratio (β42/40 ratio), were further evaluated in AD patients. Neurogranin levels were found to be associated to varying extents with T-tau (rho = 0.808, p < 0.001), P-tau (rho = 0.655, p < 0.001) and β42/40 ratio (rho = −0.592, p = 0.001) (Table 2). Moreover, neurogranin was also found to be moderately and inversely associated with Mini-Mental State examination (MMSE) score (rho = −0.474; p = 0.012).
score (rho = 0.808, < 0.001). Neurogranin levels were found to be associated to varying extents with T-tau (rho = 0.808, < 0.001), phosphorylated tau at threonine 181 (P-tau) and amyloid β4. Discussion

Figure 2. ROC curve of neurogranin for AD diagnosis. Dashed line indicates reference line.

Table 2. Correlation analysis among CSF biomarkers in AD patients.

|            | Neurogranin | T-tau      | P-tau      | β42       | β40       | β42/40 Ratio |
|------------|-------------|------------|------------|-----------|-----------|--------------|
| Neurogranin| 0.808       | 0.655      | 0.053      | 0.321     | −0.592    |              |
| T-tau      | p < 0.001   | p < 0.001  | p = 0.780  | p = 0.118 | p = 0.001 |
| P-tau      | p < 0.001   | −0.030     | p = 0.877  | p = 0.221 | −0.492    |              |
| β42        | 0.013       | 0.333      | 0.463      | p = 0.010 | −0.024    | p = 0.908    |
| β40        | p < 0.001   | p = 0.104  | p = 0.947  |           |           |              |
| β42/40 ratio|            |            |            |           |           |              |

4. Discussion

Neurodegenerative diseases are an important health burden and their early identification is crucial, but this is still challenging today. CSF biomarkers represent precious tools for assessing neurodegenerative disorders, providing in vivo information on the underlying pathology [23–27]. Specifically, CSF is an ideal biofluid due to its proximity to the brain parenchyma, the lower intrinsic protease activity than blood, the moderately low cost in comparison to positron emission tomography (PET) imaging and the safety of lumbar puncture. To date, CSF biomarkers, including β42, β42/40 ratio, T-tau and P-tau, have been integrated in the diagnostic work-up of AD [19]. Neurogranin has recently emerged as a promising biomarker of synaptic dysfunction, especially in AD. Thus, it could provide integrative information to the core CSF biomarkers for AD management. It could also give important information for longitudinal monitoring of disease progression and drug effects on synaptic degeneration in clinical trials of disease-modifying therapies for AD.

It is noteworthy that although literature evidence encourages the introduction of neurogranin as biomarker of synaptic dysfunction, efforts are still required before implementing it in clinical practice. An essential issue is the definition of its RI. Indeed, the clinical laboratory test result has no value in isolation and, consequently, RI and decisional cut-off value are mandatory for appropriately interpreting the laboratory data [28–32].
However, especially for CSF biomarkers, establishing an RI is an arduous task due to the difficulties of obtaining such biological fluid in healthy individuals. In this study, we established the RI of neurogranin in a population of controls and individuals with non-neurodegenerative neurological diseases, which were not characterized by synaptic degeneration and, consequently, should not influence neurogranin levels. We applied the robust method, as suggested by the IFCC/CLSI document, when the number of individuals was lower than 120 [33]. The lower and upper reference limits of the RI, calculated by the robust method with bootstrapped 90% CI, were 2.9 (90%CI 0.25–10.1) and 679 (90%CI 595–779), respectively. In addition, we established 319 pg/mL as the decisional cut-off value of neurogranin for diagnosing AD. At this cut-off value, neurogranin showed good diagnostic accuracy, with an AUC of 0.78, and a sensitivity and specificity of 0.73. Finally, we found a strong correlation between neurogranin and CSF biomarkers of synapsis loss, T-tau and P-tau, as well as with MMSE. Whereas synapse loss and neuronal degeneration are pathogenic mechanisms interrelated in AD, it has been suggested that the evaluation of biomarkers reflecting both processes should be performed. Overall, our findings support the use of neurogranin as a biomarker of synaptic dysfunction.

In this study, we included only patients with AD, as a model of neurodegenerative diseases. Indeed, AD represents the most common form of dementia in the general population worldwide. Additionally, we did not compare AD with other dementia or neurodegenerative diseases, such as Lewy bodies dementia and Parkinson’s disease. Thus, we could not state that neurogranin is a specific biomarker of AD and further studies must be performed to assess whether neurogranin could be used as a biomarker for differential diagnosis among neurodegenerative diseases. Recently, Willems et al. showed that neurogranin did not differentiate AD from non-AD dementia in two dementia cohorts, one included clinical AD and non-AD patients with high CSF tau levels and the other included patients with a definite post-mortem diagnosis, independently from CSF biomarkers [34]. The authors concluded that neurogranin could reflect a general pathophysiological process of synaptic degeneration and it was not specific for AD. On the contrary, Portelius et al. found that neurogranin was significantly increased in AD patients compared with patients with non-AD neurodegenerative diseases, including Parkinson’s disease and frontotemporal dementia [35]. Additionally, they showed that increased levels of neurogranin were associated with greater Aβ neuritic plaque and tau tangle pathology scores. Thus, the authors concluded that neurogranin could be a specific biomarker of AD. Overall, a definite conclusion on the specificity of neurogranin for AD could not be drawn, and further studies are required to address such question. To date, neurogranin certainly represents a biomarker of synaptic degeneration in AD.

Our findings are in accordance with previous studies, which showed good accuracy of neurogranin for AD, with an AUC ranging from 0.696 to 0.85 (Table 3). It is noteworthy that the decisional cut-off value, as well as the sensitivity and specificity, have not been specified in most of the studies, making it difficult to compare findings among studies.

The limitation and strengths in our study must be mentioned. The small number of AD is the main limitation, while the well-characterized patient groups, the use of a validated assay and the appropriate pre-analytical sample handling represent strengths in our study. It is noteworthy that the established cut-off value of neurogranin is based only on statistical calculation (Youden index). When considering the RI, a different cut off maybe selected based on the desired specificity and/or sensitivity. The validity of the cut-off value established in our study shall be confirmed in further studies by using an external validation cohort, including patients classified according to laboratory and clinical findings.

To the best of our knowledge, this is the first study defining the RIs of CSF neurogranin levels. We measured CSF neurogranin by a commercially available ELISA kit. Thus, it is plausible that using different ELISA kits or analytical methods, the RI could be slightly different. Thus, the RI established in our study can be transferred to other laboratories only after appropriate verification [28].
Table 3. Studies on the accuracy of CSF neurogranin for AD diagnosis.

| Study Population | Assay | AUC | Sensitivity | Specificity | Optimal Cut-Off Value (pg/mL) |
|------------------|-------|-----|-------------|-------------|-------------------------------|
| Xue et al. [36]  | 111 cognitively-normal controls, 193 MCI, 95 AD | Electrochemiluminescence technology using Ng7 | 0.71 | NA | NA | NA |
| Fan et al. [37]  | 65 cognitively-normal controls, 65 AD | Electrochemiluminescence technology using Ng7 | 0.783 | NA | NA | NA |
| Galasko et al. [38] | 90 normal controls, 46 AD | ELISA (EUROIMMUN, Lübeck, Germany) | 0.504 | 0.200 (0.022–0.311) | 0.854 (0.640–0.932) | 167.78 |
| Schipke et al. [39] | 20 MDD, 20 AD | In-house ELISA | 0.696 | NA | NA | NA |
| Mattsson et al. [40] | 93 controls, 93 AD | 2-site immunoassay uses an affinity-efficient trapping and purification technique for polyclonal antibodies | 0.71 | NA | NA | NA |
| Tarawneh et al. [41] | 207 controls, 95 AD | In-house ELISA | 0.85 | NA | NA | 254.7 |
| Janelidze et al. [42] | 74 AD | In-house ELISA | 0.761 | NA | NA | NA |

MCI, mild cognitive impairment; AD, Alzheimer’s disease; NA, not available; ELISA, enzyme-linked immunosorbent assay; MDD, major depressive disorder.

Author Contributions: Conceptualization, L.A. and M.C.; patient enrollment, T.P. and V.L.B.; CSF analysis, C.M.G. and R.V.G.; statistical analysis, M.V.; writing—original draft preparation, L.A. and A.M.C.; writing—review and editing, B.L.S., G.B. and C.S.; supervision, M.C. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Ethics Committee of University Hospital “Paolo Giaccone” (Institutional Ethic Committee Palermo 1 n.° 07/2017).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The datasets generated during and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Watson, J.B.; Battenberg, E.F.; Wong, K.K.; Bloom, F.E.; Sutcliffe, J.G. Subtractive cDNA cloning of RC3, a rodent cortex-enriched mRNA encoding a novel 78 residue protein. J. Neurosci. Res. 1990, 26, 397–408. [CrossRef]
2. Xiang, Y.; Xin, J.; Le, W.; Yang, Y. Neurogranin: A Potential Biomarker of Neurological and Mental Diseases. Front. Aging Neurosci. 2020, 12, 584743. [CrossRef] [PubMed]
3. Jeon, S.G.; Kang, M.; Kim, Y.S.; Kim, D.H.; Nam, D.W.; Song, E.J.; Mook-Jung, I.; Moon, M. Intrahippocampal injection of a lentiviral vector expressing neurogranin enhances cognitive function in SXFAD mice. Exp. Mol. Med. 2018, 50, e461. [CrossRef]
4. Pak, J.H.; Huang, F.L.; Li, J.; Balschun, D.; Reymann, K.G.; Chiang, C.; Westphal, H.; Huang, K.P. Involvement of neurogranin in the modulation of calcium/calmodulin-dependent protein kinase II, synaptic plasticity, and spatial learning: A study with knockout mice. Proc. Natl. Acad. Sci. USA 2000, 97, 11232–11237. [CrossRef]
5. Hayashi, Y. Long-term potentiation: Two pathways meet at neurogranin. EMBO J. 2009, 28, 2859–2860. [CrossRef]
6. Zhong, L.; Cherry, T.; Bies, C.E.; Florence, M.A.; Gerges, N.Z. Neurogranin enhances synaptic strength through its interaction with calmodulin. EMBO J. 2009, 28, 3027–3039. [CrossRef]
7. Aghello, L.; Gambino, C.M.; Lo Sasso, B.; Bivona, G.; Milano, S.; Ciacchì, A.M.; Piccoli, T.; La Bella, V.; Ciaccì, M. Neurogranin as a Novel Biomarker in Alzheimer’s Disease. Lab. Med. 2021, 52, 188–196. [CrossRef] [PubMed]
8. Colom-Cadena, M.; Spires-Jones, T.; Zetterberg, H.; Blennow, K.; Caggiano, A.; DeKosky, S.T.; Fillit, H.; Harrison, J.E.; Schneider, L.S.; Scheltens, P.; et al. The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease. Alzheimers Res. Ther. 2020, 12, 21. [CrossRef] [PubMed]
9. Del Prete, E.; Beatto, M.F.; Campese, N.; Giampietri, L.; Siciliano, G.; Ceravolo, R.; Baldacci, F. Fluid Candidate Biomarkers for Alzheimer’s Disease: A Precision Medicine Approach. J. Pers. Med. 2020, 10, 221. [CrossRef] [PubMed]
10. Fyfe, I. Alzheimer disease: Neurogranin in the CSF signals early Alzheimer disease and predicts disease progression. Nat. Rev. Neurol. 2015, 11, 609. [CrossRef]
11. Hellwig, K.; Kvartsberg, H.; Portelius, E.; Andreasson, U.; Oberstein, T.J.; Lewczuk, P.; Blennow, K.; Kornhuber, J.; Maler, J.M.; Zetterberg, H.; et al. Neurogranin and YKL-40: Independent markers of synaptic degeneration and neuroinflammation in Alzheimer’s disease. *Alzheimer’s Res. Ther.* 2015, 7, 74. [CrossRef] [PubMed]

12. Kester, M.I.; Teunissen, C.E.; Crimmins, D.L.; Herries, E.M.; Ladenson, J.H.; Scheltens, P.; van der Flier, W.M.; Morris, J.C.; Holtzman, D.M.; Fagan, A.M. Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer’s Disease. *JAMA Neurol.* 2015, 72, 1275–1280. [CrossRef] [PubMed]

13. Portelius, E.; Zetterberg, H.; Skillbäck, T.; Törnqvist, U.; Andreasson, U.; Trojanowski, J.Q.; Weiner, M.W.; Shaw, L.M.; Mattisson, N.; Blennow, K.; et al. Cerebrospinal fluid neurogranin: Relation to cognition and neurodegeneration in Alzheimer’s disease. *Brain* 2015, 138, 3373–3385. [CrossRef] [PubMed]

14. Brureau, A.; Blanchard-Bregeon, V.; Pech, C.; Hamon, S.; Chaillou, P.; Guillemot, J.-C.; Barneoud, P.; Bertrand, P.; Pradier, L.; Rooney, T.; et al. NF-L in cerebrospinal fluid and serum is a biomarker of neuronal damage in an inducible mouse model of neurodegeneration. *Neurobiol. Dis.* 2017, 104, 73–84. [CrossRef] [PubMed]

15. Bacioglu, M.; Maia, L.F.; Preische, O.; Schelle, J.; Apel, A.; Kaeser, S.A.; Schweighauser, M.; Eninger, T.; Lambert, M.; Pilotto, A.; et al. Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases. *Neuron* 2016, 91, 56–66. [CrossRef] [PubMed]

16. Dhiman, K.; Blennow, K.; Zetterberg, H.; Martins, R.N.; Gupta, V.B. Cerebrospinal fluid biomarkers for understanding multiple aspects of Alzheimer’s disease pathogenesis. *Cell Mol. Life Sci.* 2019, 76, 1833–1863. [CrossRef]

17. Dulewicz, M.; Kulczyńska-Przybik, A.; Mroczko, B. Neurogranin and VILIP-1 as Molecular Indicators of Neurodegeneration in Alzheimer’s Disease: A Systematic Review and Meta-Analysis. *Int. J. Mol. Sci.* 2020, 21, 8335. [CrossRef] [PubMed]

18. Rabbito, A.; Dulewicz, M.; Kulczyńska-Przybik, A.; Mroczko, B. Biochemical Markers in Alzheimer’s Disease. *Int. J. Mol. Sci.* 2020, 21, 2019. [CrossRef]

19. Jack, C.R., Jr.; Bennett, D.A.; Blennow, K.; Carrillo, M.C.; Dunn, B.; Haeberlein, S.B.; Holtzman, D.M.; Jagust, W.; Jessen, F.; Karlawish, J.; et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. *Alzheimer’s Dement.* 2018, 14, 535–562. [CrossRef] [PubMed]

20. McKhann, G.M.; Knopman, D.S.; Chertkow, H.; Hyman, B.T.; Jack, C.R., Jr.; Kawas, C.H.; Klunk, W.E.; Korte, D.H.; Manly, J.J.; Mayeux, R.; et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. *Alzheimer’s Dement.* 2011, 7, 263–269. [CrossRef] [PubMed]

21. Albert, M.S.; DeKosky, S.T.; Dickson, D.W.; Dubois, B.; Feldman, H.H.; Fox, N.C.; Gerdanst, A.; Holtzman, D.M.; Jagust, W.J.; Petersen, R.C.; et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. *Alzheimer’s Dement.* 2011, 7, 270–279. [CrossRef]

22. Del Campo, M.; Mollenhauer, B.; Bertolotto, A.; Engelborghs, S.; Hampel, H.; Simonsen, A.H.; Kapaki, E.; Kruse, N.; Le Bastard, N.; Lehmann, S.; et al. Recommendations to standardize preanalytical confounding factors in Alzheimer’s and Parkinson’s disease cerebrospinal fluid biomarkers: An update. *Biomark. Med.* 2012, 6, 419–430. [CrossRef] [PubMed]

23. Allegri, R.F. Moving from neurodegenerative dementias, to cognitive proteinopathies, replacing “where” by “what” … *Dement. Neuropsychol.* 2020, 14, 237–242. [CrossRef] [PubMed]

24. Camporesi, E.; Nilsson, J.; Brinkmalm, A.; Becker, B.; Ashton, N.J.; Blennow, K.; Zetterberg, H. Fluid Biomarkers for Synaptic Dysfunction and Loss. *Biomark. Med.* 2015, 1177271920950319. [CrossRef]

25. Agnello, L.; Colletti, T.; Lo Sasso, B.; Vidali, M.; Spataro, R.; Gambino, C.M.; Giglio, R.V.; Piccoli, T.; Bivona, G.; La Bella, V.; et al. Tau protein as a diagnostic and prognostic biomarker in amyotrophic lateral sclerosis. *Eur. J. Neurol.* 2021, 28, 1868–1875. [CrossRef]

26. Colletti, T.; Agnello, L.; Spataro, R.; Guccione, L.; Notaro, A.; Lo Sasso, B.; Blandino, V.; Graziano, F.; Gambino, C.M.; Giglio, R.V.; et al. Prognostic Role of CSF β-amyloid 1-42/1-40 Ratio in Patients Affected by Amyotrophic Lateral Sclerosis. *Brain Sci.* 2021, 11, 302. [CrossRef] [PubMed]

27. Agnello, L.; Piccoli, T.; Vidali, M.; Cuffaro, L.; Lo Sasso, B.; Iacolino, G.; Giglio, V.R.; Lupo, F.; Alongi, P.; Bivona, G.; et al. Diagnostic accuracy of cerebrospinal fluid biomarkers measured by chemiluminescent enzyme immunoassay for Alzheimer disease diagnosis. *Scand. J. Clin. Lab. Invest.* 2020, 80, 313–317. [CrossRef]

28. Henny, J.; Vassault, A.; Boursier, G.; Vukasovic, I.; Mesko Brguljan, P.; Lohmander, M.; Ghita, I.; Andreu, F.A.; Kroupis, C.; Srongl, L.; et al. Recommendation for the review of biological reference intervals in medical laboratories. *Clin. Chem. Lab. Med.* 2016, 54, 1893–1900. [CrossRef] [PubMed]

29. Bivona, G.; Agnello, L.; Ciaccio, M. Vitamin D and Immunomodulation: Is It Time to Change the Reference Values? *Ann. Clin. Lab. Sci.* 2017, 47, 508–510. [CrossRef] [PubMed]

30. Agnello, L.; Bellia, C.; Sasso, B.L.; Papetti, A.; Muratore, M.; Scaczone, C.; Bivona, G.; Lippi, G.; Ciaccio, M. Establishing the upper reference limit of Galectin-3 in healthy blood donors. *Biochem. Med.* 2017, 27, 030709. [CrossRef]

31. Agnello, L.; Bellia, C.; Lo Sasso, B.; Papetti, A.; Muratore, M.; Scaczone, C.; Bivona, G.; Lippi, G.; Ciaccio, M. Reference interval of monocyte distribution width (MDW) in healthy blood donors. *Clin. Chim. Acta* 2020, 510, 272–277. [CrossRef] [PubMed]
32. Agnello, L.; Bellia, C.; Scazzone, C.; Bivona, G.; Iacolino, G.; Gambino, C.M.; Muratore, M.; Lo Sasso, B.; Ciaccio, M. Establishing the 99th percentile for high sensitivity cardiac troponin I in healthy blood donors from Southern Italy. *Biochem. Med.* 2019, 29, 020901. [CrossRef] [PubMed]

33. Ceriotti, F.; Henny, J. “Are my Laboratory Results Normal?” Considerations to be Made Concerning Reference Intervals and Decision Limits. *EJIFCC* 2008, 19, 106–114. [PubMed]

34. Willemsen, E.; Sieben, A.; Somers, C.; Vermeiren, Y.; De Roeck, N.; Timmers, M.; Van Broeckhoven, C.; De Vil, B.; Cras, P.; De Deyn, P.P.; et al. Neurogranin as biomarker in CSF is non-specific to Alzheimer’s disease dementia. *Neurobiol. Aging* 2021, 108, 99–109. [CrossRef] [PubMed]

35. Portelius, E.; Olsson, B.; Höglund, K.; Cullen, N.C.; Kvartsberg, H.; Andreasson, U.; Zetterberg, H.; Sandelius, Å.; Shaw, L.M.; Lee, V.; et al. Cerebrospinal fluid neurogranin concentration in neurodegeneration: Relation to clinical phenotypes and neuropathology. *Acta Neuropathol.* 2018, 136, 363–376. [CrossRef] [PubMed]

36. Xue, M.; Sun, F.R.; Ou, Y.N.; Shen, X.N.; Li, H.Q.; Huang, Y.Y.; Dong, Q.; Tan, L.; Yu, J.T.; Alzheimer’s Disease Neuroimaging Initiative. Association of cerebrospinal fluid neurogranin levels with cognition and neurodegeneration in Alzheimer’s disease. *Aging* 2020, 12, 9365–9379. [CrossRef]

37. Fan, Y.; Gao, Y.; Therriault, J.; Luo, J.; Ba, M.; Zhang, H.; Alzheimer’s Disease Neuroimaging Initiative. The Effects of CSF Neurogranin and APOE ε4 on Cognition and Neuropathology in Mild Cognitive Impairment and Alzheimer’s Disease. *Front. Aging Neurosci.* 2021, 13, 667899. [CrossRef] [PubMed]

38. Galasko, D.; Xiao, M.; Xu, D.; Smirnov, D.; Salmon, D.P.; Dewit, N.; Vanbrabant, J.; Jacobs, D.; Vanderstichele, H.; Vanmechelen, E.; et al. Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer’s disease. *Alzheimer’s Dement.* 2019, 5, 871–882. [CrossRef]

39. Schipke, C.G.; De Vos, A.; Fuentes, M.; Jacobs, D.; Vanmechelen, E.; Peters, O. Neurogranin and BACE1 in CSF as Potential Biomarkers Differentiating Depression with Cognitive Deficits from Early Alzheimer’s Disease: A Pilot Study. *Dement. Geriatr. Cogn. Disord.* 2015, 8, 277–289. [CrossRef]

40. Mattsson, N.; Insol, P.S.; Palmqvist, S.; Portelius, E.; Zetterberg, H.; Weiner, M.; Blennow, K.; Hansson, O.; Alzheimer’s Disease Neuroimaging Initiative. Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer’s disease. *EMBO Mol. Med.* 2016, 8, 1184–1196. [CrossRef]

41. Tarawneh, R.; D’Angelo, G.; Crimmins, D.; Herries, E.; Griest, T.; Fagan, A.M.; Zipfel, G.J.; Ladenson, J.H.; Morris, J.C.; Holtzman, D.M. Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease. *JAMA Neurol.* 2016, 73, 561–571. [CrossRef] [PubMed]

42. Janelidze, S.; Hertz, J.; Zetterberg, H.; Landqvist Waldö, M.; Santillo, A.; Blennow, K.; Hansson, O. Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer’s disease. *Ann. Clin. Transl. Neurol.* 2015, 3, 12–20. [CrossRef] [PubMed]